Sign in
Taking people in PolandPhase 2

Tests nivolumab followed by chemotherapy and stem cell transplant in Hodgkin lymphoma

Tests nivolumab, then chemotherapy and stem cell transplant, in adults with returning Hodgkin lymphoma.

Key facts

Who runs it
Medical University Of Gdansk
Where
Cracow, Gdansk, Gliwice, Katowice, Lodz, Olsztyn, Warsaw, and Wroclaw, PolandSee the 9 sites
Registry title
Use of nivolumab (N) followed by chemotherapy: bendamustine, gemcitabine and dexamethasone (BGD) with autologous bone marrow transplantation in patients with Hodgkin’s lymphoma refractory to 1-line therapy.
Status
Recruiting
Phase
Phase 2
People taking part
84 people, planned
Started
1 Dec 2022
Planned end
28 Feb 2026
Type of study
Interventional
Record updated
5 November 2024

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with classical Hodgkin's lymphoma that did not respond to first-line treatment or came back after it. It tests nivolumab, then BGD chemotherapy, then a stem-cell transplant.

Age
18 years or older
Sex
All sexes
Disease stage
Classical Hodgkin's lymphoma that is refractory to first-line treatment or has relapsed. Stage IIA with a large tumor volume (>147 ml) or a lesion over 10 cm (3.9 in), or stage IIB-IV. At least one measurable lesion. ECOG 0-2.
Earlier treatment
Must have had first-line chemotherapy. The lymphoma either stayed active (positive iPET2, Deauville 4 or 5) or came back within three months of finishing it.

Main reasons for not taking part

  • Non-classical Hodgkin's lymphoma, or transformation into another lymphoma
  • HIV infection, or active HBV, HCV or CMV infection
  • Pregnancy or breastfeeding
  • Central nervous system involvement
  • Heart failure NYHA>2 or LVEF<45%

The registry criteria, word for word

Show all 22 criteriaShow less

Who can take part

  • Patients with recurrence of previously confirmed histopathologically confirmed classical Hodgkin's lymphoma based on the local pathology report according to the WHO 2016 classification, after the first line of treatment initially diagnosed in stage IIA but with a large metabolic tumor volume or the presence of a massive lesion (>10cm) or diagnosed in stage IIB- IV OR Patients with primary refractory classical Hodgkin's lymphoma in stage IIA with a large metabolic tumor volume (>147 ml) or the presence of a massive lesion (>10 cm) or in stage IIB-IV. Primary resistance to treatment will be defined by a positive iPET2 test (Deauville scale scores 4 and 5) performed after the 2nd cycle of first-line chemotherapy; and in patients with a negative iPET2 test result (Deauville scale scores 1, 2, 3) the occurrence of active disease confirmed by PET-CT within three months of the end of first-line chemotherapy
  • Evaluation of disease advancement by PET examination at diagnosis
  • Age ≥18 years old
  • ECOG 0-2
  • Presence of at least one measurable change
  • Consent to effective contraception during the study using contraception for 14 months for women and 11 months for men after the last dose of immuno-chemotherapy
  • In women of childbearing age, a negative serum pregnancy test result at screening and consent to use highly effective methods of contraception during the study and for 14 months after the last dose of chemotherapy (except for patients over 50 years of age with natural amenorrhea for a period of at least 12 months or after bilateral salpingoophorectomy or hysterectomy)
  • Signing consent to participate in the clinical trial

Who cannot take part

  • Medical contraindications or patient's refusal to consolidate BGD rescue treatment with aHCT
  • HIV infection, active HBV, HCV, CMV infection. In the case of hepatitis B infection and the presence of abHBc, it is necessary to evaluate the PCR DNA of the virus and start prophylactic treatment in accordance with the advice of an infectious disease doctor
  • Known hypersensitivity to any of the drugs used in the treatment
  • Failure to perform PET scans during induction treatment in accordance with the inclusion criteria
  • Other cancer - active form or less than 5 years from cure
  • Uncontrolled diabetes
  • Liver failure (bilirubin 1.5 x ULN, SGOT > 5 x ULN) if unrelated to lymphoma, and Gilbert's syndrome
  • Heart failure NYHA>2 or LVEF<45%
  • Non-classical form of Hodgkin's lymphoma
  • Pregnancy or breastfeeding
  • The patient is unable to sign the informed consent form to participate in the study
  • Performance status according to ECOG>2
  • Transformation of Hodgkin's lymphoma into another lymphoma
  • Central nervous system involvement

Where in Poland

  • Samodzielny Publiczny Zaklad Opieki Zdrowotnej Szpital Uniwersytecki W KrakowieCracow, PolandTaking people
  • Uniwersyteckie Centrum KliniczneGdansk, PolandTaking people
  • Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie Panstwowy Instytut BadawczyGliwice, PolandTaking people
  • Samodzielny Publiczny Szpital Kliniczny Im.Andrzeja Mieleckiego SUM W KatowicachKatowice, PolandTaking people
  • Wojewodzkie Wielospecjalistyczne Centrum Onkologii i Traumatologii im. M. Kopernika w LodziLodz, PolandTaking people
  • Szpital Kliniczny Ministerstwa Spraw Wewnętrznych i Administracji z Warmińsko - Mazurskim Centrum Onkologii w OlsztynieOlsztyn, PolandTaking people
  • Instytut Hematologii I TransfuzjologiiWarsaw, PolandTaking people
  • Narodowy Instytut Onkologii im Marii Sklodowskiej Curie Panstwowy Instytut BadawczyWarsaw, PolandTaking people
  • Uniwersytecki Szpital Kliniczny im Jana Mikulicza Radeckiego we WroclawiuWroclaw, PolandTaking people

About the trial

What the trial wants to find out

To evaluate the efficacy and safety of the intervention based on early initiation of second-line treatment (Nivolumab) in patients with Hodgkin's lymphoma resistant to previously administered treatment, followed by BGD chemotherapy (2 cycles) and consolidation with autologous transplantation of hematopoietic stem cells (aHCT). Additionally, the predictive value of circulating free DNA of Hodgkin's lymphoma cells measured before autologous transplantation will be assessed.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
Use of nivolumab (N) followed by chemotherapy: bendamustine, gemcitabine and dexamethasone (BGD) with autologous bone marrow transplantation in patients with Hodgkin’s lymphoma refractory to 1-line therapy.
Plain-language title
Tests nivolumab followed by chemotherapy and stem cell transplant in Hodgkin lymphomaGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
5 November 2024